Search results
3 days ago · Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.
3 days ago · The U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early Alzheimer’s, making it the second therapy for slowing progression of the brain-wasting disease...
4 days ago · Eli Lilly is gearing up to launch its Alzheimer’s drug for use in early-stage patients after receiving US approval on Tuesday, offering the medicine at a steep premium to a competitor as it...
4 days ago · After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Biogen’s...
3 days ago · The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people...
3 days ago · On Tuesday, the FDA approved Eli Lilly and Co’s (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer’s disease.
3 days ago · The US Food and Drug Administration (FDA) approved a drug made by Eli Lilly on Tuesday that is designed to treat the early symptoms of Alzheimer's disease.
